Journal of Viral Hepatitis最新文献

{"title":"Exploration of a Model for Elimination of Hepatitis C in Women of Childbearing Age in Primary Hospitals in Southern China","authors":"Li Guo,&nbsp;Wenbin Wu,&nbsp;Wen Zhou,&nbsp;Ruiting Liang,&nbsp;Yan lin,&nbsp;Yuting Chen,&nbsp;Yuping Wu,&nbsp;Jing Fei,&nbsp;YingPing Chen,&nbsp;Liyun Ruan,&nbsp;Houyang Zeng,&nbsp;Bihua Gao","doi":"10.1111/jvh.70153","DOIUrl":"10.1111/jvh.70153","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis C virus (HCV) can be transmitted from mother to child, although data on HCV elimination in women of childbearing age remain limited. This study aimed to evaluate an intervention model aligning with the ‘treatment as prevention’ strategy. The ‘Hepatitis C Prevention and Treatment Project for Women of Childbearing Age (15–49 years)’, launched in October 2022, strengthened the use of HCV-Ab screening, RNA testing, and treatment referral through multidisciplinary hospital collaborations. Key indicators (screening, RNA testing, and treatment rates) were compared between the pre-intervention (October 2021–September 2022) and post-intervention (October 2022–September 2023) periods. Additionally, a retrospective analysis of 503 HCV-Ab-positive women diagnosed between 2015 and 2024 was performed, together with a recall of the patients for RNA testing and treatment. The post-intervention rates for screening rose from 41.5% to 66.2%, while those for RNA testing increased from 45.9% to 97.9%, and treatment from 52.6% to 97.3% (all <i>p</i> &lt; 0.001). Among the 503 historical cases, 337 (67.0%) returned for follow-up, with 92.5% completing RNA testing (312/337), 65.1% found to be RNA-positive (203/312) and 91.3% began treatment (185/203). Of these, 98.9% (183/185) achieved SVR12 after direct-acting antiviral therapy. Another 124 (24.7%) agreed to future testing. These findings demonstrated that targeted interventions significantly improve the rates of HCV diagnosis and treatment in women of childbearing age, enabling early detection and reducing the risk of transmission. This model offered a practical approach to eliminating HCV in this population, fulfilling the ‘treatment as prevention’ goal.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Patients and Factors Associated With the Development of Hepatitis C Virus-Associated Hepatocellular Carcinoma in an Urban, Primary-Care Based Hepatitis C Clinic","authors":"Kathryn Thompson,&nbsp;James Thompson,&nbsp;Lesley S. Miller","doi":"10.1111/jvh.70169","DOIUrl":"10.1111/jvh.70169","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic hepatitis C virus infection (HCV) is one of the leading causes of hepatocellular carcinoma (HCC) in the United States. Using a retrospective cross-sectional analysis, this study identified patient characteristics and factors associated with the development of HCV-associated HCC in 113 patients seen in the primary care-based HCV clinic in Grady Memorial Hospital, a public, safety-net healthcare facility in Atlanta, Georgia from October 2013 to November 2024. The study population was comprised of mostly African American men with high rates of polysubstance use, 96.5% of whom had cirrhosis. Patients treated for HCV prior to HCC diagnosis were older at HCC diagnosis (mean difference 3.248, <i>p</i>-value 0.037), had a longer latency period between HCV and HCC diagnoses (mean difference 38.740, <i>p</i>-value 0.002), had prior HCC screening (mean difference 0.547, <i>p</i>-value 0.000), and less time from last HCC screening to HCC diagnosis (mean difference −25.332, <i>p</i>-value 0.012), and had a lower Child-Pugh Score at time of HCC diagnosis (mean difference −0.300, <i>p</i>-value 0.036) compared to patients who were not treated for HCV. For patients who achieved SVR prior to HCC, HCV genotype 1 was associated with longer time to HCC diagnosis (<i>p</i>-value 0.030), and a higher FIB-4 index at the time of achieving SVR and longer knowledge of HCV infection were associated with shorter time to developing HCC (<i>p</i>-value 0.003; <i>p</i>-value 0.044). Ultimately, this study highlights the importance of understanding risk factors for HCV-associated HCC in underserved populations which could help providers tailor their approach to mitigate the risk of HCC.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological Considerations in Prevalence Meta-Analysis of Hepatitis B Among Migrants","authors":"Hemant Singh Thakur,&nbsp;Vikas Yadav","doi":"10.1111/jvh.70171","DOIUrl":"10.1111/jvh.70171","url":null,"abstract":"","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing Pattern of HDV Infection in Italy Over 40 Years; the Current Scenario and the Impending Challenge","authors":"Gian Paolo Caviglia,&nbsp;Tommaso Stroffolini","doi":"10.1111/jvh.70172","DOIUrl":"10.1111/jvh.70172","url":null,"abstract":"<p>Since the initial description of HDV, in the last four decades Italy has witnessed a profound decline of the infection driven by HBV vaccination, contrasted however by the reconstitution of a viral reservoir through migratory flows from endemic HDV areas; in parallel, the medical scenario has changed, resulting in different clinical outcomes. The epidemiological and clinical changes were documented by national surveys performed up to 2025, which provided an ongoing perspective on the long-term evolution of HDV, highlighting the temporal trends in prevalence, risk factors, and clinical features. This review summarises the changes over time of HDV in Italy and the contemporary epidemiologic features of an infection that is vanishing among natives but increasing among migrants, outlining the medical challenge of a new heterogeneous clinical spectrum, including indolent phenotypes.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12993911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-Administration of Hepatitis C Direct-Acting Antivirals and Enzyme-Inducing Antiepileptic Drugs: Real-World Experience From a Multi-Centre Case Series","authors":"R. Harrison,&nbsp;S. Patel,&nbsp;F. Marra,&nbsp;A. Francisco,&nbsp;H. Boothman,&nbsp;Y. Kim,&nbsp;R. Kamiri-Ngugi,&nbsp;J. Lacey,&nbsp;J. Henry,&nbsp;A. Boyle","doi":"10.1111/jvh.70168","DOIUrl":"10.1111/jvh.70168","url":null,"abstract":"<div>\u0000 \u0000 <p>The management of hepatitis C virus (HCV) infection in patients requiring ongoing enzyme-inducing antiepileptic drugs (eiAEDs) presents a therapeutic challenge due to potential drug–drug interactions with direct-acting antivirals (DAAs). Evidence regarding DAA treatment efficacy in this context remains limited. This case series examined the outcomes of patients with HCV who continued their eiAED therapy while being treated with conventional regimens of DAAs. A total of 23 patients with HCV were treated with standard doses and durations of HCV DAAs in combination with eiAEDs. High treatment adherence was reported for 19 (82.6%) patients and 21 (91.3%) achieved sustained virological response; two were lost to follow-up. Despite potential for reduced DAA levels, no virological failures or serious adverse events were observed in patients attending follow-up. This represents the largest reported single case series involving concomitant use of eiAEDs and DAAs. The findings provide reassurance that standard-dose DAA treatment can be effective even when co-administered with eiAEDs.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HBV RNA Predicts the Risk of Off-Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta-Analysis","authors":"Dong-Hui Wang,&nbsp;Jia-Lan Wang,&nbsp;Su-Wen Jiang,&nbsp;Ai-Wu Zhou,&nbsp;Meng-Han Jin,&nbsp;Hao-Jin Zhang,&nbsp;Shi-Qi Yang,&nbsp;Shi-Yang Fan,&nbsp;Ai-Rong Hu","doi":"10.1111/jvh.70167","DOIUrl":"10.1111/jvh.70167","url":null,"abstract":"<p>Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment. This study aims to provide recommendations for monitoring relapse after treatment cessation, while also elucidating the significance of HBV RNA in predicting relapse in CHB patients. Studies published between 2019 and 2025 were searched using PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang, and Cqvip. There are 21 cohort studies included and 2043 individuals involved. In our study, HBV RNA-positive individuals had a 1.9-fold higher viral relapse (VR) rate and a 2.26-fold higher clinical relapse (CR) rate compared to negative patients (all <i>p</i> &lt; 0.0001). Subgroup analyses indicated that HBeAg positive at baseline was associated with higher rates of CR (<i>p</i> = 0.006) and no significant correlation between longer follow-up period following the cessation of NAs therapy (≥ 2 years) and higher VR or CR. For each log10 copies/ml increase in HBV RNA levels at discontinuation, there was a 1.32-fold increase in VR and a 1.37-fold increase in CR (all <i>p</i> &lt; 0.0001). Our findings evaluated the relationship between HBV RNA status and levels at the time of NAs discontinuation and post-discontinuation relapse, highlighting HBV RNA as a helpful post-treatment biomarker for predicting relapse. HBV RNA surveillance is essential for patients discontinuing therapy following NAs, particularly for those who are HBeAg-positive at baseline.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12988316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan","authors":"Sabeen Shah,&nbsp;Nyashadzaishe Mafirakureva,&nbsp;Adam Trickey,&nbsp;Aliya Hasnain,&nbsp;Uzma Khan,&nbsp;Saira Khowaja,&nbsp;Hiba Ashraf,&nbsp;Naila Baig-Ansari,&nbsp;Matthew Hickman,&nbsp;Peter Vickerman,&nbsp;Josephine G. Walker,&nbsp;Aaron G. Lim","doi":"10.1111/jvh.70164","DOIUrl":"10.1111/jvh.70164","url":null,"abstract":"<p>Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan. Data on patients (<i>n</i> = 1288, median age 40 years) initiating direct-acting antiviral (DAA) treatment (October 2016 to December 2018) were extracted from hospital records. Eligible patients had chronic HCV, were treatment naïve, and without hepatic decompensation. Multivariable logistic regression analysed factors associated with treatment outcomes (not completing treatment, treatment completion without sustained virological response test at 12 weeks (SVR12) visit, and treatment completion with SVR12). Costs (2019 USD) were estimated using micro-costing from financial records and staff interviews. Among 1288 patients (63% women), 93% (1200/1288) completed treatment, and 74% (884/1200) attended SVR12 visit, with 98% (<i>n</i> = 870/884) cured. Compared with 0–29 year-olds, incomplete treatment was lower among 30–49 year-olds (aOR 0.47 [0.26–0.83]) and ≥ 50 year-olds (aOR 0.48 [0.24–0.93]). SVR12 non-attendance was higher for 24-week versus 12-week regimens (aOR: 3.46 [1.51–7.93]), but lower for patients with APRI scores 0.5–1.49 (aOR 0.69 [0.50–0.96]) and ≥ 1.5 (aOR 0.44 [0.24–0.78]) compared to 0–0.49. The mean treatment cost was $370.74 per patient, driven by clinic visits $271.80 (73.3%), labs $68.32 (18.4%), and DAAs $30.62 (8.3%). Overall, a high treatment completion and cure rate were achieved, with a low average cost per patient, indicating that this HCV treatment model can be affordable and may be considered for widescale treatment scale-up in Pakistan.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12980558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147434081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B Vaccine Response in Children of Vaccinated Versus Unvaccinated Mothers: A Retrospective Cohort Study","authors":"Safa Shibli,&nbsp;Mohamad Suki,&nbsp;Tannous Korzom,&nbsp;Manfred S. Green,&nbsp;Rifaat Safadi","doi":"10.1111/jvh.70165","DOIUrl":"10.1111/jvh.70165","url":null,"abstract":"<p>Universal infant hepatitis B (HBV) vaccination is highly effective in preventing infection. However, little is known about whether a mother's HBV vaccination history influences her child's immune response to routine immunisation. We aimed to compare vaccine-induced antibody responses in children of vaccinated and unvaccinated mothers. We conducted a historical-retrospective cohort study of 364 children who completed the standard infant HBV vaccination series and underwent post-vaccination antibody testing. Maternal vaccination status was determined by serology, medical records and cohort year. Children were classified as offspring of HBsAg-negative vaccinated mothers (<i>n</i> = 92), HBsAg-negative unvaccinated mothers (<i>n</i> = 174), or HBsAg-positive mothers (<i>n</i> = 98), who also received hepatitis B immunoglobulin (HBIG) at birth. Anti-HBs titers were analysed and categorised. Ordinal logistic regression was used to assess associations. Overall seroprotection rates (≥ 10 mIU/mL) were high (89.3%) and did not differ significantly between groups. However, children born to mothers vaccinated prior to pregnancy were significantly more likely to achieve very high antibody levels (≥ 1000 mIU/mL) compared with children of unvaccinated mothers or those who received HBIG at birth (<i>p</i> &lt; 0.05). This association was most pronounced in children tested at ≤ 3 years of age. Mean anti-HBs titers were also highest in offspring of vaccinated mothers. While older maternal age and lower haemoglobin levels impaired the response, the HBIG did nothing. While infant HBV seroprotection rates were uniformly high regardless of maternal background, children born to mothers vaccinated against HBV prior to pregnancy exhibited a more robust early antibody response (≥ 1000 mIU/mL). These findings suggest a possible intergenerational enhancement of vaccine responsiveness and may affect long-term implications for HBV vaccination strategies.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12973348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Model for Hepatitis C Elimination: CDC-Dispatching Follow-Up Coordinators Stationed in Hospitals","authors":"Jingcheng Xu,&nbsp;Yi Cao,&nbsp;Yingqi Xiao,&nbsp;Weiqing Li,&nbsp;Minchang He,&nbsp;Yongchun Li","doi":"10.1111/jvh.70163","DOIUrl":"10.1111/jvh.70163","url":null,"abstract":"<div>\u0000 \u0000 <p>This study aimed to establish and evaluate a three-tiered closed-loop management model for hepatitis C involving ‘CDC-community-follow-up coordinators’, so as to improve the referral rate and DAA treatment rate for previously diagnosed but untreated (DBU) patients, enhance the diagnosis and treatment coverage for in-hospital HCV antibody-positive patients, and accelerate the elimination of hepatitis C. In April 2024, the novel ‘CDC-community-stationed follow-up coordinators’ model for hepatitis C management was launched in Nanhai District, Foshan City, with the CDC coordinating the recall of historical DBU patients; through government-procured third-party follow-up services, stationed follow-up coordinators were assigned to Nanhai District People's Hospital to facilitate the follow-up, diagnosis and treatment of both in-hospital patients and external DBU patients, while comparisons were conducted between pre- and post-implementation periods regarding HCV RNA testing rates, DAA treatment rates and diagnosis-to-treatment delays, and treatment adherence and completion rates across different populations were assessed. A total of 4975 DBU patients between 2004 and 2024 were identified from the CDC database, and after 3 months of telephone follow-up, the response rate was 38.21% (1901/4975), the recall rate 23.55% (401/1703), the HCV RNA positivity rate 25.69% (103/401), and the DAA treatment rate 54.4% (56/103). After the implementation of the model, the in-hospital HCV RNA testing rate for anti-HCV-positive patients increased from 68.1% (738/1084, January 2022–March 2024) to 90.97% (393/432, April–December 2024), and the DAA treatment rate rose from 43.1% (116/269, January 2022–March 2024) to 76.7% (92/120, April–December 2024); the mean time from antibody positivity to RNA testing decreased from 19.3 days to 11.0 days, and the time from diagnosis to treatment initiation shortened from 42.2 days to 22.6 days. The CDC-dispatching stationed follow-up coordinator model enables effective link-to-care for DBU patients and significantly improves the diagnosis and treatment rates of in-hospital HCV cases, demonstrating strong potential for scaling up in resource-limited settings.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged Intrahepatic Cholestasis After Acute Hepatitis E Infection: A Case Series and Genetic Analysis","authors":"Montserrat Fraga,&nbsp;Sophie Kasmi,&nbsp;Susanne N. Weber,&nbsp;Roman Liebe,&nbsp;Christine Sempoux,&nbsp;Ali Saadat,&nbsp;Jacques Fellay,&nbsp;Silke Kenngott-Kelber,&nbsp;Vincent Zimmer,&nbsp;Frank Lammert,&nbsp;Marcin Krawczyk,&nbsp;Christoph Jüngst","doi":"10.1111/jvh.70156","DOIUrl":"10.1111/jvh.70156","url":null,"abstract":"<p>Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide. Whereas HEV infection is typically self-limiting, rare cases of prolonged cholestasis have been reported. The underlying mechanisms remain unclear, though host genetic variation may contribute. This study aimed to investigate the role of genetic predisposition in HEV-induced prolonged cholestasis by analysing variants in genes associated with hepatocanalicular transport. We performed a retrospective review of medical records from three university centres in Switzerland and Germany and identified five immunocompetent patients with prolonged cholestasis following acute HEV infections. Genetic analysis using next-generation sequencing included a panel of five genes involved in cholestatic liver diseases (<i>ATP8B1, ABCB11</i>, <i>ABCB4, ABCC2</i> and <i>MYO5B</i>). Variant frequencies were evaluated using population reference databases and compared with a genetically characterised cohort of asymptomatic HEV-infected blood donors. All five patients were male, with a median age of 59 years. The median duration of cholestasis exceeded 77 days. Two patients exhibited potentially pathogenic heterozygous variants: <i>ATP8B1</i> p.N45T in one patient and <i>MYO5B</i> p.K429R in another. Additionally, common <i>ABCB11</i> variants were detected in all patients, which might have contributed to cholestatic clinical presentation. In the asymptomatic HEV-infected controls, the <i>MYO5B</i> p.K429R variant was absent, whereas the <i>ATP8B1</i> p.N45T variant was detected in only one individual in a heterozygous state. These case series illustrate that host genetics might influence the severity of HEV infection, particularly prolonged cholestatic jaundice. Further research is needed to explore the interaction between viral infections and host genetics in liver disorders.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12969245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}